IN2014KN02981A - - Google Patents
Info
- Publication number
- IN2014KN02981A IN2014KN02981A IN2981KON2014A IN2014KN02981A IN 2014KN02981 A IN2014KN02981 A IN 2014KN02981A IN 2981KON2014 A IN2981KON2014 A IN 2981KON2014A IN 2014KN02981 A IN2014KN02981 A IN 2014KN02981A
- Authority
- IN
- India
- Prior art keywords
- treatment
- acs
- pharmaceutical compositions
- compositions used
- acute coronary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261672439P | 2012-07-17 | 2012-07-17 | |
PCT/US2013/049703 WO2014014706A1 (en) | 2012-07-17 | 2013-07-09 | Nicotinamide derivate in the treatment of acute coronary syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014KN02981A true IN2014KN02981A (hu) | 2015-05-08 |
Family
ID=48794245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2981KON2014 IN2014KN02981A (hu) | 2012-07-17 | 2013-07-09 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20150209337A1 (hu) |
EP (1) | EP2874627A1 (hu) |
JP (1) | JP2015522612A (hu) |
KR (1) | KR20150036631A (hu) |
CN (1) | CN104507478A (hu) |
AU (1) | AU2013290577A1 (hu) |
BR (1) | BR112015000964A2 (hu) |
CA (1) | CA2879222A1 (hu) |
IN (1) | IN2014KN02981A (hu) |
RU (1) | RU2014152454A (hu) |
WO (1) | WO2014014706A1 (hu) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9707219B2 (en) | 2013-07-10 | 2017-07-18 | Glaxosmithkline Intellectual Property (No.2) Limited | Losmapimod for use in treating glomerular disease |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
WO2019071144A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9711643D0 (en) * | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US7125898B2 (en) | 2002-02-12 | 2006-10-24 | Smithkline Beecham Corporation | Nicotinamide derivatives useful as p38 inhibitors. |
GB0318814D0 (en) * | 2003-08-11 | 2003-09-10 | Smithkline Beecham Corp | Novel compounds |
-
2013
- 2013-07-09 IN IN2981KON2014 patent/IN2014KN02981A/en unknown
- 2013-07-09 KR KR1020157003956A patent/KR20150036631A/ko not_active Application Discontinuation
- 2013-07-09 EP EP13737782.6A patent/EP2874627A1/en not_active Withdrawn
- 2013-07-09 AU AU2013290577A patent/AU2013290577A1/en not_active Abandoned
- 2013-07-09 JP JP2015523123A patent/JP2015522612A/ja active Pending
- 2013-07-09 CN CN201380038150.5A patent/CN104507478A/zh active Pending
- 2013-07-09 US US14/414,798 patent/US20150209337A1/en not_active Abandoned
- 2013-07-09 RU RU2014152454A patent/RU2014152454A/ru not_active Application Discontinuation
- 2013-07-09 CA CA2879222A patent/CA2879222A1/en not_active Abandoned
- 2013-07-09 WO PCT/US2013/049703 patent/WO2014014706A1/en active Application Filing
- 2013-07-09 BR BR112015000964A patent/BR112015000964A2/pt not_active IP Right Cessation
-
2016
- 2016-09-02 US US15/255,356 patent/US20160367542A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2014014706A1 (en) | 2014-01-23 |
JP2015522612A (ja) | 2015-08-06 |
BR112015000964A2 (pt) | 2017-06-27 |
RU2014152454A (ru) | 2016-09-10 |
AU2013290577A1 (en) | 2015-02-26 |
KR20150036631A (ko) | 2015-04-07 |
US20160367542A1 (en) | 2016-12-22 |
CN104507478A (zh) | 2015-04-08 |
EP2874627A1 (en) | 2015-05-27 |
CA2879222A1 (en) | 2014-01-23 |
US20150209337A1 (en) | 2015-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2548873B (en) | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome | |
CA2956871C (en) | Compounds active towards bromodomains | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
MX2015009104A (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
MX2020005181A (es) | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). | |
EP2847152A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF METABOLIC SYNDROME | |
MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
PH12016502291A1 (en) | Indolizine derivatives as phosphoinositide 3-kinases inhibitors | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
MA40460A (fr) | Ciblage lysosomial et utilisation correspondante | |
UA115357C2 (uk) | Похідні піридин-4-ілу | |
UA112760C2 (uk) | Теобромін у комбінації з гвайфенезином для лікування кашлю | |
MX2016004078A (es) | Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih). | |
MX2015013755A (es) | Formulacion farmaceutica para uso en el tratamiento y/o prevencion de restenosis. | |
IN2014KN02981A (hu) | ||
IN2014DE02625A (hu) | ||
MX345263B (es) | Formulación de pexiganan estable. | |
RS55061B1 (sr) | Novi derivati amino-pirolina i njihova upotreba u prevenciji i/ili lečenju metaboličkog sindroma | |
TN2014000484A1 (en) | Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis. | |
PH12016500541A1 (en) | Use of odiparcil in the treatment of a mucopolysaccharidosis |